USEF is working with agencies helping equine populations following the aftermath of hurricanes in the southeast. If you want to aid their efforts, please donate to our Equine Disaster Relief Fund at usef.org/donate.
  • Share:

US Equestrian Announces Requirements for Use of FDA-Approved Zimeta™ (Dipyrone Injection)

by US Equestrian Communications Department | Dec 31, 2019, 12:00 PM

Lexington, Ky. - Kindred Biosciences, Inc. announced the drug, Zimeta™ (dipyrone injection), has been approved for use in horses for the control of pyrexia (fever) by the U.S. Food and Drug administration’s Center for Veterinary Medicine.

Dipyrone is a non-steroidal anti-inflammatory drug (NSAID); however, it is not one of the seven quantitatively restricted NSAIDs currently addressed by USEF Equine Drugs and Medications Rules. As such, it is a prohibited substance, but GR411 (Conditions For Therapeutic Administrations of Prohibited Substances) will apply. Any use of Zimeta™ (dipyrone injection) will require a properly filed medication report form documenting a 24-hour withdrawal. Additionally, the administration of dipyrone will not constitute the use of a second NSAID, which is prohibited by USEF rules. This policy is effective immediately.

For questions, please call the USEF Equine Drugs and Medications Program at 800-633-2472.